Making Ramadhan Fasting a Safer Experience With Technology Study
NCT02189135 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 85
Last updated 2016-12-16
Summary
Type 2 diabetes mellitus (T2DM) is a chronic condition that is one of the major causes of illness, disability, and death in Malaysia with an increasing prevalence. Despite the best effort, only 1 in 3 patients ever meet their HbA1c goal. In most patients with type 2 diabetes, the use of oral anti-diabetics is a mainstay in therapy. However, there is a risk of hypoglycaemia in most patients taking these drugs. This is especially important in T2DM Muslims wishing to fast during Ramadan as the dietary pattern changes to one large meal at sunset called 'Iftaar' and a light meal before dawn called 'Sahur'. Most Muslims will generally consume large quantities of fried and sugary foods when they break their fast or during the night. Given the importance and public health significance of poor diabetes management and its associated risk especially during Ramadan, the investigators aim to test the intervention of using remote monitoring within community provider practice for patients with T2DM. The investigators hypothesize that the combined use of a mobile enable glucometer which can directly feedback the patients glycaemic levels to the physicians will reduce and even eliminate the occurrence of hypoglycaemia whilst ensuring that patients remain euglycaemic throughout the whole Ramadan month.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
Interventions
- DEVICE
-
Telemedicine
The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
Sponsors & Collaborators
-
Segi University
collaborator OTHER - lead OTHER
Principal Investigators
-
Shaun Lee, PhD · Monash University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-07-31
- Primary Completion
- 2016-09-30
- Completion
- 2016-09-30
Countries
- Malaysia
Study Locations
More Related Trials
-
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
NCT05029115 ·Status: ENROLLING_BY_INVITATION
-
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
NCT01020123 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol
NCT07043816 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
NCT01496430 ·Status: TERMINATED ·Phase: PHASE3
-
Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin
NCT02135549 ·Status: COMPLETED ·Phase: NA
-
A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
NCT02851849 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
NCT01452451 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate 24-hr Glucose After OD vs BD AZD1656
NCT00819884 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM
NCT07020949 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
NCT02175784 ·Status: COMPLETED ·Phase: PHASE4
-
GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
NCT00261352 ·Status: TERMINATED ·Phase: PHASE3
-
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin
NCT02053103 ·Status: TERMINATED ·Phase: PHASE2
-
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
NCT00318656 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
NCT00499707 ·Status: COMPLETED ·Phase: PHASE3
-
To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes
NCT01176097 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
NCT02653599 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
NCT00817778 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test
NCT01936025 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)
NCT02935712 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
NCT02946632 ·Status: UNKNOWN ·Phase: PHASE3
-
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
NCT04219124 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of ZT002 in Healthy Participants
NCT05491421 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
NCT00995787 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
NCT01456195 ·Status: COMPLETED ·Phase: PHASE3
-
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
NCT05731544 ·Status: COMPLETED ·Phase: PHASE1/PHASE2